Medical Pharmacology: Immunopharmacology Practice Questions

Medical Pharmacology: Immunopharmacology Practice Questions

Proliferation-Signal Inhibitors II (Sirolimus (rapamycin) and Everolimus)

Click on the correct answer.

Sirolimus (Rapamune) and drug interactions:
1. Serolimus doses may have to be adjusted if the drug is administered with other drugs that may induce synthesis of the P450 drug metabolizing enzyme isoform CYP3A4.
2. Serolimus dosage may have to be reduced if other drugs that inhibit CYP3A4 or P-glycoprotein activity (such as diltiazem, a calcium channel blocker)
3. Both
4. Either
Serolimus toxicity:
1. In the context of renal transplantation, serolimus exhibits a dose-dependent increase in triglycerides in serum cholesterol (may require therapy).
2. The use of cyclosporine in combination with sirolimus may result in more renal dysfunction compared to cyclosporine as monotherapy.
3. Both
4. Neither
Serolimus administration may increase proteinuria and therefore should be used cautiously in those individuals exhibiting GFR <30% or have pre-existing proteinuria.
1. True
2. False
Toxicity/toxicities associated with the proliferation signal inhibitor class which includes both serolimus and everolimus.
1. Myelosuppression, notably thrombocytopenia
2. Liver toxicity
3. Both
4. Neither
mTOR Inhibitor/inhibitors:
1. Everolimus
2. Zotarolimus
3. Both
4. Neither
Everolimus (Zortress and others): clinical use/uses
1. Astrocytoma treatment
2. Breast cancer treatment
3. Both
4. Neither
Everolimus (mTOR inhibitor) administration, if given with a calcineurin inhibitor, may result in reduced kidney function to greater extent than seen with calcineurin inhibitor treatment by itself.
1. True
2. False
Patients receiving serolimus exhibit:
1. Increased risk of infection
2. Increased risk of lymphoma
3. Both
4. Neither
Sirolimus administration especially when used in combination with an ACE inhibitor may cause angioedema.
1. True
2. False
Serolimus is contraindicated in pregnancy due to its antiproliferative action.
1. True
2. False

Previous Immunopharmacology Practice Question Set

Next Immunopharmacology Practice Question Set

If you wish to return to the Table of Contents in ENGLISH, press the RETURN button above.

Otherwise, if the text is NOT displayed in English and you are ready to leave this page, Press here to return to the Table of Contents

Source Material:
- Rothlin C Gutkind J Chapter 39 Immunosuppressants, Immunomodulation and Tolerance In Goodman & Gilman's The Pharmacological Basis of Therapeutics (Brunton LL Knollman BC eds) McGraw Hill LLC (2023).
- Lake D & Briggs A Ch 55 Immunopharmacology in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023.
- Chrouos G Ch 39 Adrenocorticosteroids & Adrenocortical Antagonists in Katzung's Basic & Clinical Pharmacology (Vanderah TW, ed) 16e McGraw Hill 2023
- Brezinski E Klickstein L Armstrong A Ch 46 Pharmacology of Immunosuppression in Principles of Pharmacology: The Pathophysiologic Basis of Drug Therapy. (Golan DE Armstrong EJ Armstrong AW, eds) 4e 2017 ls) 4e 2017
- Ritter JM Flower R Henderson G Loke YK MacEwan D Robinson E Fullerton J Ch 54 Anti-inflammatory and Immunosuppressant Drugs Rang & Dale's Pharmacology 10e Elsevier 2024.
- Burchum J Rosenthal L Lehne's Pharmacology for Nursing Care Ch 72 Immunosuppressants Elsevier 2022.
- Burchum J Rosenthal L Lehne's Pharmacology for Nursing Care Ch 75 Glucocorticoids in Nonendrocrine Disorders Elsevier 2022.
- Bass A Rogatsky Ch 32 Immunomodulatory Drugs in Goldman-Cecil Medicine (Goldman L Schafer, eds) Elsevier 26e 2020
- Leiva M Takemoto Ch 238 Immunosuppressants in Lippincott Illustrated Reviews: Pharmacology 8e ((Walen et al, eds) Wolters Kluwer 2023.
- Hall J Hall M Ch 78 Adrenocortical Hormones Guyton and Hall Textbook of Medical Physiology 14e Elsevier 2021.